Form 4: Stoke Therapeutics Director Exercises Stock Options and Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Arthur A. Levin reports exercising stock options and changes in beneficial ownership of Stoke Therapeutics, Inc. shares.
Summary
- On March 31, 2025, Arthur A. Levin, a director of Stoke Therapeutics, Inc., executed transactions involving the company's stock.
- Levin exercised restricted stock units, acquiring 1,210 shares of common stock.
- Following these transactions, Levin directly owns 1,210 shares of common stock.
- Levin also indirectly owns 17,979 shares through the Butler-Levin Revocable Trust.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine exercise of stock options.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of the stock transaction (exercise of restricted stock units). |
| 12/31/2025 | Restricted Stock Units vest quarterly on the last day of March, June, September, and December. |
| 04/02/2025 | Date of signature for the Form 4 filing. |
Keywords
Stoke Therapeutics, Director, Stock Options, Beneficial Ownership, Form 4, STOK, Securities, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.